Stimuli-responsive codelivery of apatinib and doxorubicin potentiates chemotherapy efficacy in breast cancer

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Chinese Chemical Letters

• Publication date

  2025-10-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.cclet.2025.111936
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• In vivo deposition of poorly soluble drugs.

  2024cited by this paper
• A Targeted and Responsive Nanoprodrug Delivery System for Synergistic Glioma Chemotherapy.

  2024cited by this paper
• Towards targeting the breast cancer immune microenvironment

  2024cited by this paper
• Multifunctional Nanoparticle-Loaded Injectable Alginate Hydrogels with Deep Tumor Penetration for Enhanced Chemo-Immunotherapy of Cancer.

  2024cited by this paper
• The interplay between PEGylated nanoparticles and blood immune system.

  2023cited by this paper
• RGD-directed 24 nm micellar docetaxel enables elevated tumor-liver ratio, deep tumor penetration and potent suppression of solid tumors.

  2023cited by this paper
• cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer.

  2023cited by this paper
• Thermal-triggered loading and GSH-responsive releasing property of HBc particles for drug delivery.

  2023cited by this paper
• Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial

  2023cited by this paper
• Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer

  2023cited by this paper
• Vasculature organotropism in drug delivery.

  2023cited by this paper
• Targeting ADRB2 enhances sensitivity of non-small cell lung cancer to VEGFR2 tyrosine kinase inhibitors

  2022cited by this paper
• Matrix stiffening and acquired resistance to chemotherapy: concepts and clinical significance

  2022cited by this paper
• Effective drug combinations in breast, colon and pancreatic cancer cells

  2022cited by this paper
• NIR-II Light Leveraged Dual Drug Synthesis for Orthotopic Combination Therapy.

  2022cited by this paper
• Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy

  2021cited by this paper
• Engineering of stimuli-responsive self-assembled biomimetic nanoparticles.

  2021cited by this paper
• Apatinib inhibits glioma cell malignancy in patient-derived orthotopic xenograft mouse model by targeting thrombospondin 1/myosin heavy chain 9 axis

  2021cited by this paper
• Intratumoral VEGF nanotrapper reduces gliobastoma vascularization and tumor cell mass.

  2021cited by this paper
• Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin

  2021cited by this paper
• Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors

  2020cited by this paper
• Robust and smart polypeptide-based nanomedicines for targeted tumor therapy.

  2020cited by this paper
• Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors

  2020cited by this paper
• Breast cancer

  2019cited by this paper
• Mitochondria-targeting nanomedicine self-assembled from GSH-responsive paclitaxel-ss-berberine conjugate for synergetic cancer treatment with enhanced cytotoxicity.

  2019cited by this paper
• Core-Shell Distinct Nanodrug Showing On-Demand Sequential Drug Release To Act on Multiple Cell Types for Synergistic Anticancer Therapy.

  2019cited by this paper
• Co-delivery of docetaxel and doxorubicin using biodegradable PEG-PLA micelles for treatment of breast cancer with synergistic anti-tumour effects

  2018cited by this paper
• Targeting the tumour stroma to improve cancer therapy

  2018cited by this paper
• Patient-derived models of acquired resistance can identify effective drug combinations for cancer

  2014cited by this paper

• No citing papers are available for this paper.